Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 16 of 16 for “"Factor XIa"”.

  1. DISCOVERY AND BIOPHYSICAL CHARACTERIZATION OF ALLOSTERIC INHIBITORS OF FACTOR XIa (FXIa)

    … target the enzymes of the coagulation cascade. FXIa, a 160 kDa homodimer is gaining popularity of late as a potential target for anti-thrombotic agents due to its relative safety. A number of inhibitors which target the active site of FXIa have been reported but to our knowledge there have been …

    vcu Repository record for DISCOVERY AND BIOPHYSICAL CHARACTERIZATION OF ALLOSTERIC INHIBITORS OF FACTOR XIa (FXIa) (opens in a new tab)

  2. Total Synthesis of Clavatadine A Analogs to Produce a Viable Reversible Inhibitor for Factor XIa

    … A, selectively inhibits human blood coagulation factor XIa. As a result, the synthesis and biological testing of clavatadine A and synthetic clavatadine A analogues that selectively inhibit factor XIa would represent a new direction in cardiovascular disease research. A potent and selective …

    central-wash Repository record for Total Synthesis of Clavatadine A Analogs to Produce a Viable Reversible Inhibitor for Factor XIa (opens in a new tab)

  3. Evaluation of DOAC-Stop to Reverse the Effects of Factor XIa Inhibitors on the Activated Partial Thromboplastin Time

    Factor (F) XI is a serine protease involved in the intrinsic pathway of coagulation. This protein is an emerging target for anticoagulation due to its presumed minor role in hemostasis, but major role in thrombosis. FXI and activated FXI (FXIa) inhibitors are promising alternatives to traditional …

    mcmaster Repository record for Evaluation of DOAC-Stop to Reverse the Effects of Factor XIa Inhibitors on the Activated Partial Thromboplastin Time (opens in a new tab)

  4. Synthetic, Sulfated, Lignin-Based Anticoagulants

    … of synthetic sulfated small molecules against factor XIa – an emerging target for prophylactic anticoagulation. Our search identified a sulfated benzofuran trimer (a mimic of β-5 type linkage found in lignins) as a potent inhibitor of factor XIa. Surprisingly, this inhibitor did not compete …

    vcu Repository record for Synthetic, Sulfated, Lignin-Based Anticoagulants (opens in a new tab)

  5. Characterization of Post-translational Modifications and Resulting Structure/Function Relationships of Recombinant Human Factor IX Produced in the Milk of Transgenic Pigs

    … caused by a deficiency in or dysfunction of factor IX (FIX), a complex plasma glycoprotein required for the formation and maintenance of blood clots. Treatment of hemophilia B involves infusion of replacement FIX currently derived from two sources: FIX purified from pools of human plasma …

    vt Repository record for Characterization of Post-translational Modifications and Resulting Structure/Function Relationships of Recombinant Human Factor IX Produced in the Milk of Transgenic Pigs (opens in a new tab)

  6. The Role of Thrombin Exosites 1 and 2 in the Activation of Factor XI by Thrombin

    Factor XI (FXI) is the zymogen of the coagulation protease factor XIa (FXIa) that contributes to thrombin generation through the intrinsic pathway. FXI is activated by the contact pathway protease, factor XIIa (FXIIa), in a high molecular weight kininogen-dependent manner. It is also known to be …

    mcmaster Repository record for The Role of Thrombin Exosites 1 and 2 in the Activation of Factor XI by Thrombin (opens in a new tab)

  7. Investigations on beta 2-glycoprotein I and antiphospholipid antibodies

    … platelet surface, including binding coagulation factor XI (FXI). The implication of the interaction between β2GPI and GPIbα on platelet activation and the release of thromboxane in the presence of anti-β2GPI antibodies is explored, as well as the intracellular pathways via which this activation …

    unsw Repository record for Investigations on beta 2-glycoprotein I and antiphospholipid antibodies (opens in a new tab)

  8. A Microfluidic Approach For Evaluating Novel Antithrombotic Targets

    … to investigate the role of the contact pathway factors XII and XI, platelet-derived polyphosphate, and thiol isomerases in thrombus growth and to evaluate their potential as safer antithrombotic drug targets. The use of low level of corn trypsin inhibitor allowed the study of the contact pathway …

    penn Repository record for A Microfluidic Approach For Evaluating Novel Antithrombotic Targets (opens in a new tab)

  9. Building multiplexed genomic tools for editing and interpreting human variation

    … display. I apply this method to coagulation factor IX (FIX), the primary genetic cause of hemophilia B, to quantify variant effects on FIX secretion, identify structural constraints for folding and secretion, and apply these data to FIX variation to determine mechanisms of disease. I then …

    washington Repository record for Building multiplexed genomic tools for editing and interpreting human variation (opens in a new tab)

  10. Structural Determinants for Heparin Binding in Human Coagulation Factor XI

    Coagulation factor XI plays an important role in the consolidation phase of blood coagulation. Previous studies from our laboratory and others have demonstrated that zymogen factor XI (FXI) binds to heparin with moderate (KD~110 nM) affinity via residues (K252, K253 and K255) located in the apple 3 …

    temple Repository record for Structural Determinants for Heparin Binding in Human Coagulation Factor XI (opens in a new tab)

  11. Risk-benefit of Antithrombotic Treatment in Patients with Hemorrhage-prone Cerebral Small Vessel Disease

    … death. We assessed the treatment effect of asundexian, a factor XIa inhibitor, vs. placebo on these clinical outcomes, stratified by microbleeds presence, location, and number. I was trained on standardized rating of microbleeds on MRI, achieved excellent interrater reliability, and rated all …

    mcmaster Repository record for Risk-benefit of Antithrombotic Treatment in Patients with Hemorrhage-prone Cerebral Small Vessel Disease (opens in a new tab)

  12. Synthesis of a Library of Sulfated Small Molecules

    … three enzymes of the coagulation cascade – factors IIa, Xa and XIa – has provided a wealth of information with regard to engineering specificity for recognition of these enzymes. The screening led to the identification of CS3 which inhibited factor XIa with an IC 50 of ~ 5 μM and other …

    vcu Repository record for Synthesis of a Library of Sulfated Small Molecules (opens in a new tab)

  13. Bioengineering coagulation factor Xa substrate specificity into Streptomyces griseus trypsin

    … mutant of SGT as a starting point, coagulation factor Xa (FXa) substrate specificity determinants were then introduced by additional site-directed mutagenesis. To aid in purification of the recombinant proteases a hexa-histidine tag was added to the C-terminus of the protein. Addition of the …

    ubc Repository record for Bioengineering coagulation factor Xa substrate specificity into Streptomyces griseus trypsin (opens in a new tab) Download PDF for Bioengineering coagulation factor Xa substrate specificity into Streptomyces griseus trypsin (opens in a new tab)

  14. Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition

    … cascade through its ability to inactivate factor XIa. However, the point mutation (Met to Arg) at position 358 results in a potent thrombin inhibitor, API M358R. This mutation also enhances this serpin’s ability to inhibit the anticoagulant protein, activated protein C (APC) and hence this …

    mcmaster Repository record for Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition (opens in a new tab)

  15. ASSESSING DRUG DEVELOPMENT PROPORTIES OF ANTITHROMBOTIC AND ANTI - CANCER AGENTS

    … Several lines of evidence have suggested that factor XIa (FXIa) is a promising target for developing a new line of anticoagulants with a potentially minimal risk of bleeding [6, 7]. For example, hemophilia C patients with congenital FXI (Factor XI) deficiency are known to suffer minimal …

    vcu Repository record for ASSESSING DRUG DEVELOPMENT PROPORTIES OF ANTITHROMBOTIC AND ANTI - CANCER AGENTS (opens in a new tab)